Clinical Trials Logo

High Grade Serous Carcinoma clinical trials

View clinical trials related to High Grade Serous Carcinoma.

Filter by:

NCT ID: NCT03509246 Recruiting - Clinical trials for High Grade Serous Carcinoma

Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Start date: May 15, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous carcinoma without BRCA mutation among patients with platinum-resistant recurrent ovarian cancer.

NCT ID: NCT03462342 Recruiting - Clinical trials for High Grade Serous Carcinoma

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

CAPRI
Start date: March 9, 2018
Phase: Phase 2
Study type: Interventional

Investigational agent, AZD6738 will be given in combination with Olaparib to women with recurrent ovarian cancer (platinum-sensitive or platinum-resistant). This study will determine if using Olaparib in combination with AZD6738 is safe and tolerable and also determine the objective response rate and progression free survival of combination of AZD6738 and Olaparib in women with recurrent ovarian cancer in distinct platinum-sensitive and platinum-resistant cohorts.